Abstract
Lactate dehydrogenase (LDH) is a serum biomarker well known to correlate with disease severity in atopic dermatitis (AD). The aim of this study was to explore the cutaneous immune responses and the clinical profile of AD patients in relation to serum LDH levels. To this end, 47 untreated, adult patients with moderate-to-severe AD were stratified by median levels of serum LDH. Circulating memory T-cell responses to house dust mite (HDM) extract, in the presence of autologous lesional epidermal cells, were compared between AD subgroups. The LDHhigh group exhibited significantly higher IL-13, IL-5 and IL-9 in vitro responses confined to the cutaneous lymphocyte-associated antigen (CLA)+ subset compared to LDHlow patients. Clinically, LDHhigh patients were younger and exhibited more severe disease, elevated eosinophil counts in their blood, increased total and specific IgE levels in their plasma, and a higher prevalence of allergic rhinitis. Our data suggests that high LDH levels identify a subgroup of AD patients with a specific immune and clinical profile, and highlight the potential of LDH as a clinical parameter that may enable patient stratification for treatment selection.
Funding Information
  • FIS/ISCIII (Ministerio de Economía y Competitividad e Instituto de Salud Carlos III) (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
  • Fondo Europeo de Desarrollo Regional (FEDER) (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
  • Universitat de Barcelona (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)
  • Agency for Management of University and Research Grants of the Generalitat de Catalunya (PI21/01179, PI21/00335, PREDOCS-UB 2020, 2021 SGR 01433, FI-SDUR 2020)

This publication has 47 references indexed in Scilit: